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Activation of restingCD4+ Th cells depends upon two processes : (a) acquisition
of responsiveness to low levels ofIL-2, mediated by de novo synthesis and expression
of the p55 subunit of the IL-2-R ; and (b) biosynthesis and secretion of IL-2, the
principal autocrine cell cycle progression factor forTcells (1) . Tcells require at least
two signals for optimal IL-2 synthesis . The first signal is generated by crosslinking
oftheTCR by its specific antigen complexed toan appropriate selfMHC molecule,
an event that can be mimicked by antibodies directed at nonpolymorphic regions
of theTCR or at the associated CD3 complex . Mitogenic lectins such asPHA are
also thought to deliver a signal via theTCR/CD3 complex . Second, or "accessory"
signals can be delivered in three major ways : (a) binding of soluble cytokines such
as IL-1, IL-6, or TNF to their specific receptors (2-6), (b) binding of antibodies to
T cell surface molecules such as CD2, CD4, CD28, or CD44 (7-11) ; or (c) direct
activation of second messenger pathways by drugs such as phorbol esters (e.g .,PMA
[12]). The need for a second signal appears inversely related to the strength of the
primary signal delivered via theTCR. In the presence of a strong primary signal
such as high concentrations of immobilized anti-CD3, secondary signals may not
further enhance proliferation (13) . However, even in asystem undergoing maximal
proliferation, secondary signals such asPMA (12) or antibodies to CD28 (14) may
further augment IL-2 synthesis to "supra-optimal" levels .
Accessory cells are the physiological source ofmany of the secondary signals de-
scribed above either by the secretion of cytokines or by direct cell contact involving
interactions between specific ligand pairs . Previous work has demonstrated that en-
dothelial cells (EC) t , like classicalAPC such as lymphoid dendritic and Langerhans
cells, can activate resting T cells in a primary allogeneic response (15-19). Fibro-
blasts and smooth muscle cells, in contrast, are not able to elicit primary responses
(16-18), although fibroblasts, induced to expressMHC class II molecules with IFN-
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y, can present nominal antigen to cloned T cell lines (20). The failure of fibroblasts
to present antigen to resting T cells can be overcome by the addition of exogenous
IL-2 (21). Moreover, the addition of endothelial cells or mAb to CD28 also allows
fibroblasts to present antigen to resting T cells (19). We have shown previously that
endothelial cells, but not fibroblasts or macrophages, can markedly augment the
production of IL-2 by optimally PHA-stimulated PBMC or purified CD4` cells
(22). The augmented concentrations of IL-2 are physiologically functional since T
cells proliferate to a greater extent in the presence of EC than in the presence of
fibroblasts when the PHA concentration is suboptimal . We have proposed that EC-
mediated augmentation of IL-2 synthesis underlies the accessory role of this cell type.
The aim of this project was to establish the nature of the signal delivered by the
EC to the T cell that leads to augmented IL-2 production. Using cultures of PBMC
or purified CD4+ cells optimally stimulated with PHA, we compared the ability of
EC to deliver the appropriate signal with the ability of soluble cytokines or condi-
tioned medium. The use of PHA to drive maximally T cell proliferation allows the
dissection of the role of secondary signals in T cell activation without the complica-
tion of different proliferative rates between treatments. Cytokines that modulate T
cell responses and are produced by EC failed to mimic the effect of intact cells, and
furthermore, neither conditioned medium from resting nor cytokine-treated EC were
effective. Our results further demonstrate that there is an absolute requirement for
cell-cell contact for augmentation of IL-2 production to occur and that antibodies
to lymphocyte function-associated antigen 3 (LFA-3) and CD2 block this effect. In
addition, we demonstrate in PBMC-EC cocultures, in which T cell proliferation
and IL-2 utilization are prevented by means ofblocking antibody to the p55 subunit
of the IL-2-R, that a similar contact-dependent, CD2/LFA3 pathway is used to aug-
ment IL-2 synthesis in response to anti-CD3 antibody. Moreover, the CD2/LFA-3
pathway is also used in both the augmented proliferative responses ofPBMC to anti-
CD3 antibody and the primary proliferative response of purified CD4+ T cells to
class II MHC-expressing allogeneic EC. We conclude that EC deliver costimulatory
signals to T cells via the CD2/LFA-3 pathway and suggest that this pathway is im-
portant in the initial activation of T cells that recognize antigen or alloantigen on
the surface of vascular endothelium .
Materials and Methods
EC Culture.
￿
EC from human umbilical vein were isolated and serially passaged as previ-
ously described (23, 24) . Cells from subcultures two to five were used for these experiments.
In all experiments involving EC, wells were precoated with fibronectin (24).
Isolation ofPBMC.
￿
Heparinized venous blood from healthy human volunteers was cen-
trifuged over Lymphocyte Separation Medium (Litton Bionetics, Kensington, MD) according
to the manufacturer's instructions. PBMC were removed, washed three times, and resuspended
in assay medium.
Isolation of CD4' T Cells.
￿
PBMC, prepared as above, were depleted of monocytes and
B cells by adhesion to fibronectin-coated culture plates for 1 h at 37°C. Nonadherent cells
were decanted and depleted of CD8' T cells and CD16' NK cells by panning using anti-
bodies OKT8 (CRL 8014; American Type Culture Collection, Rockville, MD) and 3G8 (a
gift fromJay Unkeless, Mt. Sinai School of Medicine, New York, NY), respectively. Panning
plates were coated with goat anti-mouse IgG (Cappel Laboratories, Cochranville, PA). The
purity of the enriched CD4' population was checked by direct immunofluorescent labeling
with Leu-3 (anti-CD4), Leu-2 (anti-CD8), Leu-11 (anti-CD16), and Leu-M3 (anti-CDl4 forHUGHES ET AL .
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monocytes) (Becton Dickinson &Co., Mountain View, CA) and flow cytometry using aFAGS
analyzer (Becton Dickinson & Co.) .
Culture ofPBMC or CD4' Cells with EC, Cytokines, or ConditionedMedium .
￿
Freshly isolated
PBMC (10 5) were suspended in 100 Al assaymedium (RPMI 1640 containing 10% heat in-
activated FCS, 2 mM glutamine, 125 U/ml penicillin/streptomycin [all Gibco Laboratories,
Grand Island, NY] and 50 AM 2-ME [Sigma Chemical Co., St . Louis, MO]) and added
either to control wells or to wells preplated 18 h earlier with EC (1.2 x 10 4 cells/well) in
fibronectin-coated 96-well U-bottomed plates (Linbro Chemical Co ., Hamden, CT) . Wells
containing EC were washed three times beforePBMC were added . Medium containingPHA
(PHA-L ; Sigma Chemical Co.) was then added either alone, with cytokines at the indicated
concentrations, or with conditioned medium to a final volume of200 Al . The final concentra-
tion ofPHA was always 10,ug/ml, a concentration previously demonstrated to produce max-
imalT cell proliferation. In some experiments, PHA was replaced with anti-CD3 mAb(OKT3 ;
Ortho Diagnostic Systems Inc ., Raritan, NJ) at the indicated concentrations . When OKT3
was used as the stimulus for IL-2 production, blocking antibody to the p55 subunit of the
IL-2-R (antiTac; gift ofThomas Waldmann, National Institutes of Health, Bethesda, MD)
was also included at a final dilution of 1 :1,000 to prevent proliferation and IL-2 utilization .
The conditioned media used in these experiments were generated by culture ofEC in assay
medium for 2 d in the presence of cytokines or PBMC . Recombinant cytokines used were
IL-1 /3 (5 x 10 1 U/mg ; gift ofAlan Shaw, Glaxo, Geneva), IL-6, TNF (1.68 x 108 U/mg and
2.5 x 10' U/mg, respectively ; both gifts of Walter Fiers, Ghent, Belgium), and IFN-y (2.5 x
10' U/mg; Biogen, Cambridge, MA) . Conditioned media were collected from the EC cul-
tures and freeze-thawed before use . Plates were incubated for 2 d in a humidified C02 in-
cubator at 37°C, after which supernatants were collected and frozen before IL-2 and/or IL-6
quantitation .
Culture ofEC andPBMC in Transwells.
￿
EC were grown to confluence in fibronectin-coated
24-well plates (Costar, Cambridge, MA) and washed three times before use . PBMC (3 x
10 5/well) were suspended in assay medium containing PHA and added either directly to the
EC in the wells or to Transwells (Costar) suspended above the EC . In parallel wells, PBMC
were added in a similar geometry but to wells lacking EC . The final concentration ofPHA
was 10 Wg/ml. OKT3 was also used in some experiments at a final concentration of 25 ng/ml .
WhenOKT3 was used as the stimulus for IL-2 production, the cultures were concomitantly
supplemented with antiTac antibody (1 :1,000) . Plates were incubated for 2 d and superna-
tants collected as above .
Culture ofEC with PBMC or CD4' Cells in the Presence ofAntibodies.
￿
Freshly isolated PBMC
or CD4' T cells were suspended in assay medium containingPHA (10 Wg/ml final) orOKT3
(25 ng/ml) and added in triplicate to EC in 96-well U-bottomed plates as described above .
Antibodies were added in assay medium to the concentrations indicated to a final volume
of 200 A1 . mAbs were used as ammonium sulphate precipitations of ascites and were : TS
2/9 (anti-LFA-3), TS 2/18 (anti-CD2), TS 1/18 (anti-CD18), and RRIA (anti-ICAM-1) (all
IgGl ; gifts of Timothy Springer, Center for Blood Research, Boston, MA) . A nonbinding
antibody, K16/16 (IgGl ; gift ofDonna Mendrick, Brigham and Women's Hospital, Boston,
MA), was used as a control in all experiments .
Culture ofCD4' T Cells with Allogeneic EC.
￿
Confluent EC, in flat-bottomed C96 plates
(-104/well), were cultured for 3 d in the presence of IFN--y (1,000 U/ml) to induce expres-
sion ofMHC class II molecules . ContinuedEC proliferation was inhibited by treatment with
mitomycinC (10 hg/ml ; Sigma Chemical Co.) for 1 h, andHBSS three times for 1 h) immedi-
ately before addition ofT cells . Purified CD4' T cells (3 x 10 5/well) and the indicated anti-
bodies were added and the plates incubated for 6 d .
Cell Proliferation.
￿
For all experiments except those involving Transwells, duplicate plates
were run and assayed for T cell proliferation by addition of 1 .0 ACi/well [3H]thymidine (New
England Nuclear, Boston, MA) to triplicate wells for the final 6 h of culture. In cultures in-
volving allorecognition, proliferation was assessed by [ 3H]thymidine incorporation during
the final 18 h of culture. Cells were harvested using a cell harvester(PHD Technology Inc .,
Cambridge, MA), and incorporation was measured by liquid scintillation counting .
CytokineBioassays.
￿
The concentration ofcytokines in the supernatants was measured using
the IL-2-dependent murine cell line HT-2 (reference 25 ; gift of Abul Abbas, Brigham and1456
￿
AUGMENTATION OF T CELL INTERLEUKIN 2 SYNTHESIS
Women's Hospital) and the IL-6-dependent line B9.9 (reference 26; gift of David Raulet,
Massachusetts Institute of Technology, Cambridge, MA). Indicator cells were washed and
added to flat-bottomed 96-well plates (104/well for HT2, 2 x 103/well for B9 in 50 JAI). At
least five serial dilutions of each supernatant were then added to a final volume of 100 tsl.
Plates were incubated for 24 h (HT-2) or 3 d (B9), and then assayed for cell proliferation
by a colorimetric method (27) using the tetrazolium salt MTT [3-(4,5-dimethylthiazol-2-yl)-
2,5 Biphenyl tetrazolium bromide] (Sigma Chemical Co.). Standard curves were run on all
plates using rIL-2 (2.2 x 106 U/mg; Biogen) or IL-6. Concentrations of IL-2 are shown as
weighted means (28). Weighted variances were consistently <5% of the weighted mean.
mRNA Quantitation.
￿
Freshly isolated PBMC (3 x 10) were cultured with or without EC
(3 x 106) in the presence of PHA (10 Fog/ml) for the indicated times. Where PBMC were
cultured without EC, parallel plates of EC were grown and the cell lysates pooled. Whole
cell RNA was prepared by guanidinium isothiocyanate lysis and CsCI centrifugation. RNA
(25 jig/lane) was subjected to electrophoresis in 1.2% agarose containing formaldehyde and
blotted onto nitrocellulose (Schleicher & Schuell, Keene, NH). Monitoring of the 18S and
28S ribosomal bands on the nitrocellulose, by ethidium bromide staining and UV illumina-
tion, confirmed equal loading and transfer of samples. The pstl fragment from the cDNA
IL-2 clone pTCGR11 (ATCC no. 39673) was separated on low-melt agarose and 32p labeled
by random oligopriming (Boehringer Mannheim Biochemicals, Indianapolis, IN) to a specific
activity of 1-2 x 109 dpm/Ag. Blots were hybridized overnight at 43°C and then washed to
a final stringency of0.5 x SSC/0.5% SDS at 65°C. Autoradiography was for 12-72 h at - 70°C.
Results
EC Augment T Cell IL-2 Synthesis.
￿
PBMC or CD4+ T cells were cultured with
EC or soluble cytokines in the presence of a supraoptimal concentration of PHA.
Cell proliferation, as measured by [3H]thymidine uptake in each experiment, is
maximal at 10 /~g/ml PHA and is not increased further by any of the treatments
reported (data not shown). Thus, within each experiment the number of T cells
is constant among treatment conditions. In experiments where PHA was omitted,
there was no detectable proliferation or IL-2 production . In the presence of EC,
both PBMC and CD4+ cells produce considerably more IL-2 than when cultured
alone (Fig. 1). The degree of augmentation varies among donors and experiments,
but is usually between 3- and 10-fold. A similar augmentation occurs in the level
of IL-2 mRNA (Fig. 2). Message levels were maximal by 6 h and were declining
by 12 h. At both 6 and 12 h, more specific mRNA was detectable when the PBMC
had been cultured in the presence of EC. These observations establish that the aug-
mented IL-2 concentration detected in the medium results largely from an EC-
mediated increase in IL-2 synthesis.
Conditioned Medium from EC or Recombinant Cytokines Does not Augment T Cell IL-2
Production. Two cytokines were tested for their ability to mimic the effect of EC.
In the presence of supraoptimal PHA, neither IL-1/3 nor IL-6, both secreted by EC
(29-32), is able to augment IL-2 production from PBMC (Table I, Exp. 1). Like-
wise, TNF and IFN-y are also without effect (datanot shown). To test the possibility
that some other signal was being produced by the EC, either constitutively or in
response to a PBMC-derived factor, medium from resting or treated EC was added
to PBMC cultures. Medium from resting EC or EC treated with 200 U/ml TNF
has no effect on IL-2 production, although in some experiments, medium from IFN-y
(100 U/ml)-treated EC does produce a slight augmentation (Table I, Exp. 2). How-
ever, the augmentation was never comparable with that produced by coculture with
EC, and adding more conditioned medium (50% final) was no more effective (dataPBMC CD4+
I NONE EC NONE EC
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FIGURE 1 .
￿
EC augment IL-2 concentrations secreted by
both PBMC and CD4' T cells . PBMC or purified CD4*
T cells were cultured for 2 d with orwithout EC in the pres-
ence of supraoptimal concentrations ofPHA as described
in Materials and Methods . Supernatants were then assayed
for IL-2 byHT-2 bioassay. Each symbol represents a sepa-
rate experiment comparing PBMC with CD4' T cells
purified from the same donor.
not shown) . In a separate series of experiments, EC were cultured with IL-1/3 (100
U/ml), TNF(1,000 U/ml), or PBMC withoutPHA. Again, medium from cytokine-
treated cultures fails to augment IL-2 production when added to PHA-stimulated
PBMC (Table 1, Exp . 3) . Medium from EC grown with non-PHA-stimulated PBMC
has only a small effect, much less than that of viable EC . The cumulative result
of these experiments is that none of the soluble signals examined can replace EC
as a means of augmenting IL-2 synthesis .
EC Augmentation ofT Cell IL-2 Production Requires Cell-Cell Contact.
￿
To investigate
whether cell contact is necessary for augmentation and to determine whetherashort-
lived soluble signal was missed in medium transfer experiments, cells were grown
either in contact with EC, separated from EC by a Transwell membrane, or in the
absence ofEC, either above or below the membrane. These experiments establish
that cell contact is required . Only when PBMC are in direct contact with the EC
is there significant IL-2 production (Fig . 3) . As evidence that thelack ofaugmenta-
tion was not due to the inability of a soluble signal to cross the membrane, EC IL-6
production is induced by PHA-activated PBMC to comparable levels whether the
cells were in contact or separated . This experiment also confirms that the presence
of IL-6 in high concentration is not sufficient to induce augmentation .
To investigate further the nature of the interactions between EC and T cells in-
volved in thisphenomenon, variousmAbs were tested fortheir ability to inhibitaug-
FIGURE 2 .
￿
EC augment IL-2-specific mRNA in
PBMC . PBMC were cultured with or without EC
for 6 or 12 h in the presence of supraoptimal con-
centrations ofPHA . RNA was then isolated and
analyzed by Northern blotting as described in
Materials and Methods . Supernatants were also
collected and analyzed for IL-2 . Shown is one of
three similar experiments.1458
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TABLE I
Effect of EC, Cytokines, or Medium from Cytokine-treated EC
on IL-2 Production by PHA-stimulated PBMC
* IL-2 concentrations were measured by HT-2 bioassay as described in Materi-
als and Methods.
1 Stimulation index is defined as: U/ml IL-2 produced in presence of EC per
U/ml IL-2 produced in absence of EC .
§ Each experiment was repeated at least twice with similar findings.
mentation. Antibodies that block interaction between the CD2/LFA-3 ligand pair
markedly reduce the degree of augmentation seen: in some experiments by >80%
(Fig. 4). In contrast, antibodies blocking interaction between the LFA-1/ICAM-1
ligand pair have little or no effect on IL-2 production in response to PHA (Fig. 4).
To confirm that these antibodies are blocking a direct interaction between the EC
PBMC
￿
PBMC
ABOVE
￿
BELOW
TRANSWELL TRANSWELL
( no cell contact)
￿
(cellcontact)
NONE EC NONE EC
2000
1000
0
FIGURE 3.
￿
EC augmentation ofPBMC IL-2
synthesis requires cell contact. PBMC were
cultured for 2 d, either with EC, in contact
or separated by a Transwell membrane, or
without EC, in a similar geometry. All wells
contained PHA (10pg/ml). Supernatants were
collected and assayed forIL-2 or IL-6 by HT-2
or B9 bioassay, respectively. No IL-2 was de-
tectable in the absenceofPHA. EC alone pro-
duced 6 ng/ml IL-6. Shown is one of three
similar experiments.
Exp. Additions IL-2*
U/ml
Stimulation
index)
14 No additions 1 .5 1 .0
104 EC 9 .5 6 .4
IL-19 (10 U/ml) 1 .4 0.9
IL-6 (400 ng/ml) 2.4 1 .6
(2,000 ng/ml) 3.1 2.0
2 No additions 3.9 1 .0
104 EC 11 .2 2.9
25% EC-conditioned medium
Untreated EC 3.2 0.8
+ 100 U/ml IFN--y 5.4 1 .4
+ 200 U/ml TNF 3.5 0.9
+ 100/200 U/ml IFN--y/TNF 4.6 1 .2
3 No additions 3 .5 1 .0
104 EC 10.0 2 .9
25% EC-conditioned medium
Untreated EC 3 .5 1 .0
+ 105 PBMC 5.0 1 .4
+ 100 U/ml IL-1/3 2.7 0.8
+ 1,000 U/ml TNF 2.8 0.8c
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PBMC CD4+
Antibody Concentration (jAg/ml)
Anti-LFA-3
Anti-CD2
Anti-ICAM-1
Anti -CD18
FIGURE 4.
￿
EC augmentation
ofPBMC or CD4* Tcell 1L-2
production is blocked by anti-
bodies to CD2 and LFA-3.
PBMC or purified Tcellswere
cultured for2d with variousan-
tibodies, with or without EC.
All wells contained PHA (10
,ag/ml). Antibodies used were:
TS 2/9 (anti-LFA-3), TS 2/18
(anti-CD2), TS 1/18 (anti-
CD18, LFA-1 0 chain), RRIA
(anti-ICAM-1), andK16/16 (ir-
relevant isotype control). Each
line represents a separate ex-
periment.
and the IL-2-producing cells (mostly CD4+), and not an interaction involving an
intermediary cell, the experiments were repeated using purified populations of
CD4+ cells. FAGS analysis showed these populations to be effectively free ofmono-
cytes, NK cells, and CD8' cells (data not shown). As also shown in Fig. 4, EC-
augmented IL-2 production bypurified CD4+ T cells can be inhibitedby antibodies
to CD2 or LFA-3 but not by antibodies to LFA-1 or ICAM-1. Antibodies to CD4
and MHC class II also do not inhibit augmented IL-2 synthesis, consistent with
a system in which PHA stimulates the TCRCD3 complex and EC provide acces-
sorysignals. Thefailure ofantibodies toblockaugmentation in theseculturescannot
be explained by their degradation or clearance from the medium as supernatants
collected at the end ofthe culture still contained saturating concentrations of anti-
bodyas measured by indirect immunofluorescence and FAGSanalysison fresh PBMC
(data not shown).
EC-augmented TCellResponses to OKT3Involve CD2/LFA3 Interaction.
￿
Thecostim-
ulation assay using supraoptimal concentrations of PHA was developed to analyze
costimulation underconditionsofuniform(i.e., maximal) Tcellproliferation. However,
it ispossiblethat thesignals provided byPHAorothermitogeniclectins aredifferent1460
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from more specific stimuli delivered to the T cell through the TCRCD3 complex.
We therefore investigated the response of PBMC to an anti-CD3 antibody in the
presence or absence of EC. Only PBMC were examined in these experiments be-
cause purified CD4+ T cells do not respond to soluble OKT3 antibody in the ab-
sence ofFc receptor-bearing cells (data not shown). At all concentrations ofOKT3
tested, EC conferred a proliferative advantage on the T cells (Table II), leading to
an approximately threefold increase in [3I-I]thymidine incorporation in the presence
of EC. This proliferative advantage could be abrogated to a large extent by anti-
bodies to LFA-3 and CD2 (Table III). IL-2 could not routinely be detected in the
supernatants of these cultures, presumably because it is' consumed as rapidly as it
is produced. Therefore, to avoid differences in T cell proliferative rates and to pre-
vent IL-2 utilization, we added mAb to the p55 subunit of the IL-2-R (antiTac)
toour PBMC andPBMC + EC cultures. Inthe presenceofantiTacantibody, aug-
mented levels of IL-2 were detectable in cultures containing EC, and these could
be inhibited to >80% by antibodies to LFA-3 and CD2 (Table IV). In addition, ex-
periments with Transwells established that there is also a requirement for cell con-
tact in EC-mediated augmentation of IL-2 levels when OKT3 is used as the pri-
mary stimulus (Table V).
Thus, thesame phenomenon ofEC-mediated IL-2 augmentation maybeobserved
in response to the more specific but weaker stimulus provided by OKT3 as it was
TABLE II
Proliferative Response of PBMC to Anti-CD3 mAb (OKT3)
in the Presence or Absence of EC
Response on day 2
' Control antibody was K16/16 1,250 ng/ml).
1 Proliferation was measured by [ H]thymidine incorporation (1 pCi/well, 4 h).
The data are expressed as the mean oftriplicate determinations t SEM. In-
corporation by EC alone was 6.1 t 103 t 0.2 cpm (Exp. 1) and 3 .7 x
103 t 0.4 cpm (Exp. 2) . With PHA (10 Wg/ml) as the stimulus, cells incor-
porated 94.1 x 103 t 5.6 cpm and 88.3 x 103 t 5 .7 cpm with and without
EC (Exp. 1) and 125.8 x 10,3 t 9 .7 cpm and 109.3 x 103 ± 0.6 cpm with
and without EC (Exp. 2),
Exp.
1
Additions
Control'
Anti-CD3
ng/ml
(0 .05)
+
4.7
14.8
EC
cpm x
t 0.61
t 0.4
-
10-3
0.5
2.4
EC
f 0.1
t 0.2
(0 .5) 41 .4 t 6.5 13.0 t 1 .4
(5 .0) 59.6 t 4.3 16.6 t 1 .5
(50.0) 41 .3 ± 3.1 13.5 ± 0.6
(500.0) 44.9 t 2.1 13.5 ± 1 .1
2 Control 5.5 ± 0.3 0.7 ± 0.1
Anti-CD3 (0 .05) 17.0 ± 1 .1 2.1 t 0.1
(0 .5) 49.7 t 1 .4 20.5 t 1 .3
(5 .0) 77.0 t 2.6 24.4 f 1 .5
(50.0) 47.2 t 2.9 27.6 ± 2 .1
(500.0) 58.4 t 4.5 31 .7 ± 2.0HUGHES ET AL.
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TABLE III
Effect ofAntibodies to LFA-3 and CD2 on PBMC Proliferation
to Anti-CD3 Antibody in the Presence of EC
All wells contained OKT3 at 25 ng/ml.
Control antibody was K16/16 (60 ug/ml). TS 2/9 (anti-LFA-3) and TS 2/18
(anti-CD2) were used at a saturating concentration of 60 Wg/ml.
in response to the powerful mitogen PHA. In addition, these experiments demon-
strate that EC provide a proliferative advantage to OKT3-stimulated T cells that
is inhibitable by antibodies to LFA-3 and CD2.
CD4+ TCell Proliferation to Allogeneic ECInvolves CD2/LFA-3 Interaction.
￿
To inves-
tigate further the role of EC in T cell activation, we established cultures in which
purified alloreactive CD4+ T cells proliferate in response to IFN-y-treated EC. As
has been previously reported, wefound that EC stimulate proliferationofallospecific
T cells whereas fibroblasts do not. Moreover, IFN-y pretreatment ofEC to induce
expression ofclass II MHC molecules was necessary in order to see a proliferative
response. Our data indicate that this proliferative response can be significantly in-
hibited by antibodies to LFA-3 and CD2 (Table VI), providing evidence of a role
for this ligand pair in EC-supported T cell alloproliferation.
TABLE IV
Effect ofAntibodies to LFA-3 and CD2 on PBMC IL-2 Production
in Response to Anti-CD3 Antibody
- EC
+ EC
All wells contained OKT3 (25 ng/ml) and anti-Tac (1:1,000 of ascites) . No
IL-2 was detectable in the absence of anti-Tac antibody.
Cells were incubated for 24 h and supernatants assayed for IL-2 by HT-2
bioassay.
l Control antibody was K16/16 (60 ug/ml). TS 2/9 (antiLFA-3) and TS 2/18
(anti-CD2) were at 60 ug/ml.
Exp. mAb added
Response
on day 2
cpm x 10-3
Percent inhibition of
augmented response
1 -EC Control' 21 .6 t 1.4 -
+ EC Control 82.7 t 5.7 -
Anti-LFA-3 51 .5 t 4.5 51
Anti-CD2 46.6 t 4.5 59
2 - EC Control 31 .8 t 1.9 -
+EC Control 98.1 t 3.7 -
Anti-LFA-3 58.6 t 1 .2 60
Anti-CD2 83.0 t 2.8 23
mAb added
IL-2
U/ml'
Percent inhibition
of augmented
response
IL-2
U/ml
Percent inhibition
of augmented
response
Controll 1 .2 - 0.4 -
Control 2.7 - 0.8 -
Anti-LFA-3 1 .4 87 0.6 50
Anti-CD2 1 .4 87 0.6 501462
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TABLE V
Production of IL-2from OM-stimulated PBMC in Contact
with or Separatedfrom EC
PBMC/EC contact
No PBMC/EC contact
PBMC (3 x 105) were cultured either in or below Transwells, in the presence
or absence of EC cultured below the Transwell, and stimulated with OKT3
(25 ng/ml). All wells contained anti-Tac antibody (1 :1,000).
" Supernatants were collected at 24 h and assayed for IL-2 using HT-2 cells.
No IL-2 was detected in the absence of OKT3.
Stimulation index = IL-2 production in the presence ofEC / IL-2 production
in the absence o£ EC.
Discussion
Inthisreport, wehaveexamined the mechanismbywhich EC causePHA-stimulated
PBMC or CD4+ T cells to greatly increase the amounts of IL-2 secreted into the
medium. Quantitation of mRNA indicates that augmentation is mediated at the
level ofIL-2 synthesis. IL-1 and IL-6canboth modulate Tcell responses and prolifer-
ationinvitro, andboth are produced byEC (29-32). Neithercytokine,evenat supraop-
timal concentrations, was able to mimic the ability ofEC to augment IL-2 produc-
tion. Furthermore, IFN-,y, TNF, IL-1, and resting PBMC allfailed to induce asoluble
signal from EC that could mediate theeffect. CocultureofEC separated from PBMC
by a permeable membrane similarly failed to produce augmented IL-2 synthesis.
We conclude that EC transmit a signal only via a contact-dependent mechanism,
although an extremely short-lived soluble signal cannot be completely ruled out.
Antibody-blocking experiments demonstrated involvement of the receptor-ligand
pair CD2/LFA-3 in this interaction. In contrast, antibodies to ICAM-1 or LFA-1,
which can inhibit other lymphocyte functions requiring cell contact, had little or
no effect. When the more specific signal OKT3 was used as the primary stimulus,
our findings were comparable with those with PHA. That is, EC augmented IL-2
production in acontact-dependent manner involvingaCD2/LFA-3 interaction. The
CD2/LFA-3 pathwayis also usedto provideaproliferative advantage toT cells stimu-
lated with OKT3 in the presence ofEC, and may function similarly in the recogni-
tion of allogeneic EC by resting CD4+ T cells.
Although wehave used allogeneic EC as TcellstimulatorsinthePHA- andOKT3-
stimulated cultures (a restriction imposed by the use of neonatal EC), we do not
believethatrecognitionofEC alloantigens is participatingintheincreased IL-2produc-
tion. First, as wehave previously shown, only allogeneic EC and not allogeneic fibro-
blasts or monocytes increase IL-2 production from PBMC (22). Second, we only
see alloresponses (in the absence ofmitogen) after 4-7 d inculture, whereasthe PHA
and OKT3 experiments reported here were run for 1-2 d. Finally, when EC from
pooled donors were compared in the same experiment with two lines of EC from
Exp.
IL-2
U/ml"
1
Stimulation
indext
IL-2
U/ml
Exp. 2
Stimulation
index
+ EC 6.7 6.5 1 .8 4.1
-EC 1 .1 - 0.4 -
+ EC 1 .1 0.8 0.6 0.8
-EC 1 .4 - 0.8 -HUGHES ET AL.
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TABLE VI
Effect ofAntibodies to LFA-3 and CD2 on Proliferation of
CD4+ T Cells to Allogeneic EC
CD4* T cells (3 x 105/well) were cultured with allogeneic EC (IFN-y
pretreated, 1,000 U/ml, 3 d) or alone. EC proliferation was inhibited by treat-
ment with mitomycin C (10 Etg/ml for 1 h) immediately before addition ofT
cells. [3H]Thymidine (1 uCi/well) was included for the final 18 h of culture.
Proliferation of T cells alone was 0.5 x 103 t 0.1 cpm (Exp. 1) and 2.1 x
103 t 0.9 cpm (Exp. 2). No proliferation was seen on EC not pretreated with
IFN-y.
' Control antibody was K16/16 (60 F+g/ml). TS 2/9 (anti-LFA-3) and TS 2/18
(anti-CD2) were used at 60 Wg/ml.
single donors usingthe same allogeneic PBMC, an equivalent degree of augmenta-
tion and absolute level of IL-2 production were found (data not shown). Thus, the
degree ofalloantigenic difference betweenthe lymphocytesand EC is not important
in cultures stimulated by PHA or OKT3.
The requirement forcontact between EC and T cells fordelivery of an activation
signal is reminiscent of the finding of Inaba et al. (33) that dendritic cells require
contact to stimulate T cell proliferation, an effect that was similarlyLFA-1 indepen-
dent. Our antibody-blocking experiments suggest an important role forCD2/LFA-3
interaction. We do not know if the observed augmentation is being mediated by
direct signaling through CD2. Fibroblasts express comparable levels of LEA-3 (un-
published results) and yet fail to induce augmented IL-2. However, novel forms of
LFA-3, possibly involvingdifferences in glycosylation, or a second CD2 ligand present
only on EC, may represent alternative explanations for the different capabilities of
these two cell types. An additional possibility is that strengthening of cell contact
via these molecules mayallow signaling through other surface structures (34). How-
ever, use of the CD2/LFA-3 pathway simply to strengthen adhesion seems unlikely
in thecultures stimulated by PHA because the LFA-1/ICAM-1 adhesive interaction
is apparently unimportant. Furthermore, PHA is amultivalent ligand that can directly
crosslink Tcells to EC, probably bypassingthe need foradhesion molecules. Under
more physiological conditions, especially in vivo whereT cell interactions may occur
in the vascular lumen in the presence of disruptive shear forces, adhesive ligands
are likely to be much more important. Indeed, preliminary observations suggest
that even in our in vitro experiments involving OKT3 or alloantigen stimulation,
antibody to LFA-1 is partly inhibitory.
The CD2/LFA-3 interaction may not be the only signaling pathway utilized in
Exp. mAb added
Response
at day 6
cpm x 10-i
Percent
inhibition
1 + EC Control' 23.7 t 2.4 -
Anti-LFA-3 2.7 t 0.1 88
Anti-CD2 3.9 t 2.0 84
2 + EC Control 48.3 f 5.9 -
Anti-LFA-3 23.2 t 3.2 52
Anti-CD2 9.7 t 1 .2 801464
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EC accessory functions. Geppert and Lipsky (19) have demonstrated that either EC
or anti-CD28 antibody (9.3) can provide the necessary signal to allow fibroblasts
to present antigen. Ithas alsobeen shown that9.3 stabilizes mRNAsofseveralcytokines
in activated T cells, including the mRNA for IL-2 (35). Our results are consistent
with the possibility of EC signaling via CD28, although preliminary experiments
suggest that the effect of9.3 is more than additive with that ofEC. A recent report
(11) presents evidence for CD44 delivering activation signals to T cells. This is par-
ticularly interesting asCD44 mediates adhesionofTcellsto highendothelialvenules
and may deliver an early priming signal to emigrating cells. Finally, thecell contact
may involve deliveryofsignals viapathways other thanthroughmembrane proteins;
we have shown previouslythatEC actuallyappear to form gapjunctionswithclustered
T cells (36).
The observation that in vitro, EC share with dendritic cells the ability to activate
resting T cells, suggest the possibility that in vivo, there is more than one pathway
ofinitiating immune reactions depending on which accessory cell presents the an-
tigen. Dendritic cells, resident in epithelia, are believed to pick up environmental
antigens and carry them, via draining lymphatics, to lymph nodes where the an-
tigens are presented to antigen-specific T cells (37). A systemic immune reaction
may ensue. In contrast, we propose that EC pick up foreign antigens in tissues and
presentthemon their lumenal surfaceto circulatingT cells, leadingtoimmune reac-
tions localized to the site of antigenic challenge. In this context, T cell activation
in the presence ofsuboptimal concentrationsofantigen may depend upon the contact-
dependent EC-mediated augmentation ofIL-2 synthesis we have described in this
report. Inaddition, increasedIL-2 production byTcellsmayhave aregulatory effect
on the production ofvarious other cytokines involved in cell-mediated immune reac-
tions. For example, superinduction ofIL-2 by PMA increases transcription and re-
lease ofIFN-y (12), a cytokine that can convert an ineffective immune reaction to
a successful one in the skin ofleprosy patients (38). Finally, ifour hypothesis is cor-
rect that EC augmentation ofTcellIL-2 synthesis underliesinitiationofcell-mediated
immunity at peripheral sites, then use ofantibodiesordrugsthatdisrupt CD2/LFA-3
interactionmay be oftherapeuticbenefitin ameliorating localhypersensitivity reac-
tions or acute allograft rejection.
Summary
We have demonstrated that endothelial cells (EC) augment IL-2 production by
PHA-stimulated PBMC or purified CD4+ T cells and that the increase is apparent
both in the amount of soluble IL-2 secreted and in the level of specific mRNA de-
tectable by Northern blot hybridization. The ability of EC to affect levels of IL-2
cannot be reproduced by soluble factors, includingthe cytokines IL-1, IL-6, IFN-'y,
orTNF, conditioned medium from resting EC or IL-1, IFN-y- or TNF-treated EC,
orfromresting PBMC + ECcultures. Separation oftheEC andPBMC by a Trans-
well membrane demonstrated that cell contact was required for augmentation of
IL-2 synthesis and that this effect was unlikely tobe mediated by ashort-lived soluble
signal. Thecell-cell interaction requiredthe ligand pairCD2/LFA-3, sinceaugmen-
tation could be inhibited by antibodies to these structures. Antibodies to ICAM-1,
LFA-1, CD4, and MHC class II were without effect. A contact-dependent pathway
involvingCD2/LFA-3 interactions also maybeusedby ECtoaugmentIL-2 productionHUGHES ET AL.
￿
1465
from Tcells stimulated more specifically through theTCR/CD3 complexwith anti-
body OKT3. This pathway provides a proliferative advantage to T cells stimulated
with OKT3 in the presence of EC and may also be involved in the proliferative re-
sponse of resting T cells to allogeneic class II MHC-expressing EC. We propose
that EC augmentation of T cell IL-2 synthesis may be critical in the ability of EC
to elicit primary T cell antigen responses and mayhave consequences forthe devel-
opment of localized cell-mediated immune reactions.
We thankTeri Bakewell for assistance with tissue cultureandJanetAnderson forthestatistical
analyses.
Receivedfor publication 11 September 1989 and in revisedform 12January 1990.
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